Chiara Gabbiani
Chiara Gabbiani
Department of Chemistry and Industrial Chemistry
Email verificata su
Citata da
Citata da
Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs
A Bindoli, MP Rigobello, G Scutari, C Gabbiani, A Casini, L Messori
Coordination Chemistry Reviews 253 (11-12), 1692-1707, 2009
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies
S Nobili, E Mini, I Landini, C Gabbiani, A Casini, L Messori
Medicinal research reviews 30 (3), 550-580, 2010
Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium (II)− arene compounds
A Casini, C Gabbiani, F Sorrentino, MP Rigobello, A Bindoli, TJ Geldbach, ...
Journal of medicinal chemistry 51 (21), 6773-6781, 2008
Gold (III) compounds as anticancer agents: Relevance of gold–protein interactions for their mechanism of action
A Casini, C Hartinger, C Gabbiani, E Mini, PJ Dyson, BK Keppler, ...
Journal of inorganic biochemistry 102 (3), 564-575, 2008
Nanoparticles of Mg(OH)2:  Synthesis and Application to Paper Conservation
R Giorgi, C Bozzi, L Dei, C Gabbiani, BW Ninham, P Baglioni
Langmuir 21 (18), 8495-8501, 2005
Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives
M Navarro, C Gabbiani, L Messori, D Gambino
Drug discovery today 15 (23-24), 1070-1078, 2010
Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold (III) compounds with bipyridyl ligands
A Casini, MA Cinellu, G Minghetti, C Gabbiani, M Coronnello, E Mini, ...
Journal of Medicinal Chemistry 49 (18), 5524-5531, 2006
Aluminum, copper, iron and zinc differentially alter amyloid-Aβ1–42 aggregation and toxicity
S Bolognin, L Messori, D Drago, C Gabbiani, L Cendron, P Zatta
The international journal of biochemistry & cell biology 43 (6), 877-885, 2011
New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications
AR Sannella, A Casini, C Gabbiani, L Messori, AR Bilia, FF Vincieri, ...
FEBS letters 582 (6), 844-847, 2008
Gold (III) compounds as anticancer drugs
C Gabbiani, A Casini, L Messori
Gold Bulletin 40, 73-81, 2007
Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold (III) compounds for cancer treatment: a systematic study
A Casini, G Kelter, C Gabbiani, MA Cinellu, G Minghetti, D Fregona, ...
JBIC Journal of Biological Inorganic Chemistry 14, 1139-1149, 2009
Mechanisms of cytotoxicity of selected organogold (III) compounds
M Coronnello, E Mini, B Caciagli, MA Cinellu, A Bindoli, C Gabbiani, ...
Journal of medicinal chemistry 48 (21), 6761-6765, 2005
Clioquinol decreases amyloid-β burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease
C Grossi, S Francese, A Casini, MC Rosi, I Luccarini, A Fiorentini, ...
Journal of Alzheimer's disease 17 (2), 423-440, 2009
Exploring metallodrug–protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound
A Casini, C Gabbiani, E Michelucci, G Pieraccini, G Moneti, PJ Dyson, ...
JBIC Journal of Biological Inorganic Chemistry 14, 761-770, 2009
Structural characterization, solution studies, and DFT calculations on a series of binuclear gold (III) oxo complexes: relationships to biological properties
C Gabbiani, A Casini, L Messori, A Guerri, MA Cinellu, G Minghetti, ...
Inorganic chemistry 47 (7), 2368-2379, 2008
ESI–MS Characterisation of Protein Adducts of Anticancer Ruthenium (II)‐Arene PTA (RAPTA) Complexes
A Casini, G Mastrobuoni, WH Ang, C Gabbiani, G Pieraccini, G Moneti, ...
ChemMedChem: Chemistry Enabling Drug Discovery 2 (5), 631-635, 2007
ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme
A Casini, G Mastrobuoni, C Temperini, C Gabbiani, S Francese, G Moneti, ...
Chemical communications, 156-158, 2006
Auranofin, Et3PAuCl, and Et3PAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study
T Marzo, D Cirri, C Gabbiani, T Gamberi, F Magherini, A Pratesi, A Guerri, ...
ACS medicinal chemistry letters 8 (10), 997-1001, 2017
Thioredoxin reductase, an emerging target for anticancer metallodrugs. Enzyme inhibition by cytotoxic gold (III) compounds studied with combined mass spectrometry andá…
C Gabbiani, G Mastrobuoni, F Sorrentino, B Dani, MP Rigobello, A Bindoli, ...
MedChemComm 2 (1), 50-54, 2011
Exploring Metallodrug–Protein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c
A Casini, C Gabbiani, G Mastrobuoni, L Messori, G Moneti, G Pieraccini
ChemMedChem: Chemistry Enabling Drug Discovery 1 (4), 413-417, 2006
Il sistema al momento non pu˛ eseguire l'operazione. Riprova pi¨ tardi.
Articoli 1–20